PD 169316, >= 98%( HPLC ), solide

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

PD 169316 has been used for the inhibition of p38 enzyme in human hepatocytes. It has been used in culture media to promote embryoid bodies differentiation.

Biochem/physiol Actions

Potent, cell-permeable and selective p38 MAP kinase inhibitor (IC₅₀ = 89 nM).

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

PD 169316 is a pyridinyl imidazole compound. It is a potential inhibitor of p38 mitogen-activated protein kinases. It also inhibits signalling transforming growth factor β (TGFβ), particularly in human ovarian cancer cells.

Packaging

5, 25 mg in glass bottle